Xeeona Pharma Private Limited
Founded in 2020 and headquartered in Maharashtra, India.
2020 | Thane, Maharashtra (India) | Active
Xeeona Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 32.90%
- Ebitda -2542.15%
- Net Worth -9.42%
- Total Assets -15.31%
About Xeeona Pharma
Xeeona Pharma Private Limited (XPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 November 2020 (Four years and three months 23 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Home Appliances Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ravindra Kumavat and Ziyaulhaq Khan serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U52311MH2020PTC349603
- Company No.
349603
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Nov 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Home Appliances
Healthcare
Who are the key members and board of directors at Xeeona Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravindra Kumavat  | Director | 06-Nov-2020 | Current |
| Ziyaulhaq Khan | Director | 06-Nov-2020 | Current |
Financial Performance of Xeeona Pharma.
Xeeona Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 32.9% increase in profit. The company's net worth dipped by a decrease of 9.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xeeona Pharma?
Unlock access to Xeeona Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xeeona Pharma?
Xeeona Pharma has a workforce of 0 employees as of Mar 26, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xeeona Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xeeona Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.